KMT2A and leukemia: For the first time, by using the novel allosteric MAT2A inhibitor PF-9366, we were able to uncover MAT2A as both a key regulator in MLL leukemogenesis and as new therapeutic target in the treatment of poor prognosis MLLr leukemia.